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Epidemiologic data regarding pulmonary arterial hypertension (PAH) have relied on regis-
tries from Western countries. We assessed the current status of PAH in the Korean popula-
tion. The Health Insurance Review and Assessment Service (HIRA) claim database, which
comprises nationwide medical insurance data of Koreans from 2008–2016, was assessed
to determine the current status of PAH. Overall, 1,307 patients were newly diagnosed with
PAH from 2008–2016 (0.0005%, annual incidence: 4.84 patients/1 million people/year). The
mean age at diagnosis was 44±13 years (range 18–65) and patients were mostly women
(n = 906, 69.3%). Cases of idiopathic PAH (51.6%) accounted for the largest proportion, fol-
lowed by acquired PAH (APAH) associated with congenital heart disease (25.8%) and
APAH with connective tissue disease (17.2%). Overall, 807 (61.7%) patients received a sin-
gle PAH-specific treatment based on their last prescription, of which bosentan (50.6%) was
the most frequently used. Only 240 (18.4%) patients received combination therapy, with the
bosentan-beraprost combination (32.9%) being the most common. During the mean follow-
up of 1.9 years, the 1-, 2-, 3-, and 5-year estimated survival rates were 85%, 62%, 54%, and
46%, respectively. The prevalence and incidence of PAH in the Korean population is cur-
rently comparable with that in previous registries. The 5-year survival rate was slightly higher
in the Korean population than previously reported.
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Introduction
Pulmonary arterial hypertension (PAH) is a disease characterized by remodeling of the small
pulmonary arteries, which leads to a progressive increase in pulmonary vascular resistance and
right-sided heart failure and death.[1–6] Over the past decade, PAH-specific drugs such as
prostanoids, endothelin receptor antagonists (ERA), and phosphodiesterase-5 inhibitors
(PDE5-i) that can alter the natural history of PAH, have been developed [7–11]; consequently,
albeit not satisfactorily, clinical outcome of PAH has also improved.[12–14]
Several PAH registries including the Korean Registry of Pulmonary Arterial Hypertension
(KORPAH) have provided basic information on PAH in terms of its epidemiology, clinical
characteristics, and prognosis.[15–18] However, most data have derived from registries of
Western populations, thus leaving the Asian population incompletely evaluated. Further, the
natural history of PAH in the era of PAH-specific drugs and a comprehensive investigation of
the use of PAH-specific medications have not been adequately investigated.
Therefore, we assessed the prognosis and the pattern of using PAH-specific drugs in inci-
dent PAH patients, using the Korean Health Insurance Review and Assessment Service
(HIRA) database of medical claims.
Methods
National Health Insurance data of South Korea
We used data derived from the HIRA database, which consists of all medical expenses claim
data of South Koreans between 2007 and 2016 with a mean follow-up of 1.9 years.
The HIRA contains the medical billing data of the entire South Korean population (97%
health insurance, 3% medical care). In the billing statement, identifiers for the prescriber, and
the number of visits, number of days spent in outpatient visits, number of prescriptions (total
medical care costs, the partial deductible for an insured person, insurer’s contribution), details
of medical treatment items (classified by mechanism of action, drug, and treatment material),
and details of prescribed prescriptions (prescription and preparation details for each drug) are
all included.
The HIRA also contains information regarding medical history (treatments, procedures,
examinations), diagnoses, and costs of procedures or drugs. Also, all HIRA data were fully
anonymized before we accessed them. The institutional review board of the Severance Hospital
at the Yonsei University College of Medicine in Seoul, Republic of Korea approved this study
(No. 4-2017-0073). The institutional review board waived the requirement to obtain informed
consent.
Selection of incident pulmonary arterial hypertension patients
To estimate the incidence of PAH in the Korean population, Korean adults diagnosed with
PAH, aged 18–65, between 2007 and 2016 were first identified within the HIRA database.
Over this period, total Korean population aged 18–65 years was 35,927,664.
PAH was defined using the International Classification of Diseases-Tenth Revision (ICD-
10) codes and prescription of PAH-related medications, as echocardiography or right-side
catheterization results were not included in the HIRA database. Patients with PAH were
defined as subjects meeting the following two criteria: 1) subjects with a diagnosis defined by
ICD-10 codes for PAH (I27.0 and I27.2) and 2) subjects with at least one prescription of one
or more of the following drugs: a calcium channel blocker (CCB) (nifedipine, amlodipine, and
diltiazem) and a PAH-specific drug (prostanoids, ERA, and PDE5-i). Among those with a
record in the HIRA database, 14,255 patients had ICD I27.0 and I27.2 codes, of which 5,034
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had a PAH-related prescription. To determine the incidence of PAH and identify newly diag-
nosed patients, we excluded all patients with a record of a hospital visit and prescriptions
between January 1, 2007 and December 31, 2007.
As the ICD I27.0 and I27.2 codes indicate a diagnosis of pulmonary hypertension as well as
PAH. To extract only information on PAH, idiopathic PAH (IPAH) and acquired PAH
(APAH) were defined and extracted separately. We defined IPAH as having a code of I27.0
with no codes related to connective tissue disease (CTD), congenital heart disease (CHD), por-
tal hypertension, human immunodeficiency virus (HIV), schistosomiasis, or chromic hemo-
lytic anemia. Several IPAH diagnostics were included in the ICD I27.2, particularly in the
subgroup I27.2 diagnosis, where pulmonary hypertension (PH) Group 2, 3, 4, and 5 diagnoses
are included in addition to PAH (Group 1). Therefore, in order to screen only patients with
pure IPAH, patients with a left-side heart disease related diagnosis, lung disease, and/or hyp-
oxia (chronic respiratory disease, chronic thromboembolic PH, and other pulmonary artery
obstruction related ICD-10 codes are recorded in the Supplementary) were excluded. Patients
with a diagnosis of PH group 5 were also excluded.
As for APAH, we attempted to classify APAH as CTD, CHD, by ICD-10 codes related to
the disease (the ICD-10 codes used are described in S1 Table).
Other comorbidities (definitions are indicated in S2 Table), such as hypertension and dia-
betes, were also identified from the medical claims records according to the ICD-10 codes.
The following baseline demographics were collected: age at diagnosis, sex, specific etiology of
PAH, prescription medication(s), comorbid condition(s), and examination modalities (trans-
thoracic echocardiography, right heart catheterization [RHC], and cardiac magnetic resonance
imaging).
Drug codes were identified through drug nomenclature of prostanoids, ERAs, PDE5-i, and
CCB registered in the HIRA data. PAH-specific monotherapy or combination therapy was
analyzed based on the last prescribed drug for each patient. We also investigated changes in
the use of medications, as it was assumed that for some patients medications changed different
reasons (worsening symptoms, side effects, etc.).
Primary endpoint
The primary outcome was all-cause death. As the claims database contains clinical results and
classification codes, we identified deaths in the hospital using this code. Additionally, consid-
ering that the code for hospital death could be underestimated, people with no claims data for
over one year were regarded as dead. The types of PAH-specific drugs, types and frequency of
examinations related to PAH, number of hospitalizations, and length of hospital stay were ana-
lyzed. Events of all cause in-hospital mortality according to the etiology, age, and prescription
medication were surveyed.
Statistical analysis
To describe the baseline characteristics and co-morbid conditions of all PAH patients and inci-
dent PAH cases, we used frequencies (proportions) for categorical variables and means±stan-
dard deviations (SDs) for continuous variables. To compare patients’ baseline characteristics
according to PAH subgroups (IPAH or APAH), we used the independent t-test or the Wil-
coxon rank-sum test for continuous variables and the chi-square test for categorical variables.
Survival rates from enrolment of newly diagnosed patients with PAH were calculated using
the life-table method. Log-rank tests were used to compare survival rates according to PAH
subgroups (IPAH, CHD, and CTD), age, and types of medication. All-cause mortality
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according to the etiology, age, and prescription medication were analyzed using Kaplan-Meier
survival analysis. P value of<0.05 was considered statistically significant.
Results and discussion
Demographic and baseline characteristics of all patients
From January 2008 to December 2016, we identified 1,307 patients diagnosed with PAH (ICD
codes I27.0x and I27.2x) for the first time with at least one drug prescription (CCB, prostacy-
clin analogues, ERA, or PDE5-i) (Fig 1). The baseline characteristics and comorbid conditions
of all patients and their respective percentages according to the specific etiologies are summa-
rized in Table 1. The mean age at enrolment was 44±13 years for all 1,307 patients. There were
906 female patients (69.3%). The most common etiology of PAH was idiopathic (n = 674,
51.6%), followed by CHD (n = 337, 25.7%) and CTD (n = 296, 22.6%) (Fig 2). Approximately
30.0% of patients had essential hypertension and 5.8% had diabetes.
The incidence trend of PAH is shown in S1 Fig. Approximately 4 people per million people
were diagnosed as having PAH annually. In the incident cases, the distribution of patients by
age and the average follow-up duration are as follows. Based on the 2016 population of 18 to
65 years old, the incidence of PH was 4.8 per 1 million and the prevalence was 20.2 per 1
million.
Fig 1. Inclusion flow diagram of newly diagnosed pulmonary arterial hypertension patients enrolled in the study. PAH,
pulmonary arterial hypertension; ICD-10, International Classification of Diseases-Tenth Revision.
https://doi.org/10.1371/journal.pone.0209148.g001
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Primary endpoint: All-cause death
From January 1, 2008 to December 31, 2016, of the 1,307 incident cases, 581 cases (44.5%) of
mortality occurred during the mean 1.9-year follow-up. The cumulative survival curve of inci-
dent cases is presented in Fig 2. After a mean (±SD) follow-up of 1.9±1.5 years, the estimated
survival rates at 1 year, 2 years, 3 years, and 5 years were 84.9%, 62.2%, 54.3%, and 46.0%,
respectively (Fig 3A). Fig 3B presents the comparison of prognosis according to the etiologies
of PAH. IPAH patients had the highest mortality, followed by patients with CTD and CHD
(P = 0.001).
Distribution and trend of prescribed medications
Based on the last medication prescribed to each patient, 80.1% received specific treatments, of
which only 22.9% received PAH-specific monotherapy and 76.8% received PAH-specific com-
bination therapy (Table 2). In patients with APAH, bosentan was the most frequently used
drug. There was a significant difference between monotherapy and combination therapy in
patients with IPAH and those with APAH. The use of PAH target drugs was more frequent in
patients with APAH than in those with IPAH.
The rate of use of PAH-specific drugs has steadily increased every year in PAH patients. In
2009, the rate of subscribing PAH-specific drugs was 79%, compared with 40% in 2008. In
addition, the rate of prescribing PAH-specific drug combinations increased to 11% (Fig 4).
Right-sided catheterization
Right-sided catheterization (RHC) was performed in 328 patients (25.1%), which comprised
22.4% (151 patients) with IPAH and 28.0% (177 patients) with APAH. The proportion of
newly diagnosed patients who underwent RHC was 7% in 2008, but it has increased continu-
ously since then; in 2016, RHC was performed in 38% cases. (Fig 5) There were no significant
differences in the rate of RHC tests based on etiology; for both IPAH and APAH, the rates of
RHC examination increased.
Hospitalization and costs
The percentage of patients who were admitted more than once was 55.1% (n = 720). The aver-
age duration of admission was 9±7 days. The average annual total amount of medical care
Table 1. The baseline characteristics and comorbid conditions of all patients and their respective percentages according to the specific etiologies.
All patients IPAH group APAH group P-value APAH-CHD APAH-CTD-SSc APAH-CTD-SLE APAH-CTD-other
Patients, n (%) 1307 (100.0) 674 (51.6) 633 (48.4) 337 (53.2) 90 (14.2) 135 (21.3) 71 (11.2)
Age 44±13 48±12 41±12 <0.001 40±12 50±10 38±11 43±12
Female sex, n (%) 906 (69.3) 409 (60.7) 497 (78.5) <0.0001 218 (64.7) 86 (95.6) 133 (98.5) 60 (84.5)
Comorbidity
HTN, n (%) 392 (30.0) 285 (42.3) 107 (16.9) <0.0001 44 (13.1) 18 (20.0) 34 (25.2) 11 (15.5)
DM, n (%) 76 (5.8) 55(8.2) 21 (3.3) 0.0002 10 (3.0) 5 (5.6) 3 (2.2) 3 (4.2)
Renal failure (CKD), n (%) 32 (2.5) 22 (3.3) 10 (1.6) 0.0489 1 (0.3) 3 (3.3) 9 6.7) 0 (0.0)
Arrhythmia, n (%) 81 (6.2) 46 (6.8) 35 (5.5) 0.3316 1 (0.3) 0 (0.0) 1 (0.7) 2 (2.8)
TIA or stroke, n (%) 29 (2.2) 19 (2.8) 10 (1.6) 0.1285 7 (2.1) 0 (0.0) 2 (1.58) 1 (1.4)
Follow-up duration (year) 2.7±2.2 2.3±2.0 3.1±2.4 <0.0001 3.1±2.4 3.0±2.3 3.4±2.5 3.2±2.4
IPAH, idiopathic pulmonary arterial hypertension; APAH, acquired pulmonary arterial hypertension; HTN, hypertension; DM, diabetes mellitus; IHD, ischemic heart
disease; CKD, chronic kidney disease; TIA, transient ischemic attack
https://doi.org/10.1371/journal.pone.0209148.t001
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Fig 2. Pulmonary arterial hypertension etiological breakdown of patients at enrolment.
https://doi.org/10.1371/journal.pone.0209148.g002
Fig 3. Cumulative survival curve of patients with pulmonary arterial hypertension. (A) The 1-year, 2-year, and 3-year estimated survival rates shown are 84.9%,
62.2%, and 54.3%, respectively. (B). Primary outcome: cumulative survival curve of patients with pulmonary arterial hypertension according to etiology. IPAH,
idiopathic pulmonary arterial hypertension; APAH, acquired pulmonary arterial hypertension.
https://doi.org/10.1371/journal.pone.0209148.g003
Incident pulmonary artery hypertension in Korea
PLOS ONE | https://doi.org/10.1371/journal.pone.0209148 December 19, 2018 6 / 13
benefits per patient was 1,782,000 won ($16,608), and average annual deductible medical cost
per patient was 1,770,000 won ($1,649).
Discussion
The present study is the first report of clinical characteristics and epidemiology of all PAH
patients in Korea. The important findings were as follows: 1) the most common etiology of
PAH was IPAH, followed by CTD and CHD in incident cases; 2) female sex was predominant
(69.3%); 3) patients concurrently had hypertension (30.0%) and diabetes (5.8%); 4) the inci-
dence rate of PAH was 4.84 patients/1 million people; 5) the estimated mean follow-up dura-
tion was 1.9 years; and 6) 1-year, 2-year, and 3-year estimated survival rates were 85%, 63%,
and 56% respectively.
Previous large national observational registries, including the KORPAH of Korea, have pro-
vided information on current PAH epidemiology, increasing awareness about the disease.[15–
20] In the present study, it is significant that the total number of patients with PAH was inves-
tigated by using unique data on the medical expenses taking into consideration of the possibil-
ity missing unregistered patients in a previous national registry.
The demographic characteristics of the patients with PAH in the HIRA database were simi-
lar to those of the previous KORPAH registry participants. The observed mean age (44 years)
in the HIRA database was similar to that of the KORPAH registry (47.6 years), and the propor-
tion of female patients (69.3%) was less in the HIRA database than in the KORPAH registry
(80.5%). In addition, the ratio of IPAH to APAH was similar to that in other registries, includ-
ing the KORPAH. In the French and REVEAL registries, approximately half of the patients
exhibited IPAH, whereas the other half exhibited APAH.[15–17] Systemic hypertension was
the most commonly reported comorbid condition (30.0% of all patients, especially 42.3% in
IPAH patients). Similarly, in the REVEAL registry, the average diagnostic age of patients with
IPAH was 49.9 years and 80.3% of women, but the proportion of hypertension was 41.8%. In
this study, authors describe the cause of systemic hypertension in PAH patients as either a gen-
eralized vasculopathy or common substrate affecting both the pulmonary and systemic circu-
lations, such as sleep apnea or diastolic dysfunction. In other words, it is explained by other
causes besides gender and aging which are considered to be common causes of hypertension.
Table 2. The distribution of drug monotherapy and combination therapy in patients with pulmonary arterial hypertension.











Monotherapy n, (%) 807 (61.7) 397 (58.9) 410 (64.8) <0.0001 225 (66.8) 185 (62.5) 0.0003
Bosentan, n, (%) 408 (50.6) 121(30.5) 287 (70.0) <0.0001 174 (77.3) 113 (61.1) <0.0001
Beraprost, n, (%) 284 (35.2) 219 (55.2) 65 (15.9) 22 (9.8) 43 (23.2)
Sildenafil, n, (%) 58 (7.2) 25 (6.3) 33 (8.0) 23 (10.2) 10 (5.4)
Ambrisentan, n, (%) 36 (4.5) 20 (5.0) 16 (3.9) 2 (0.9) 14 (7.6)
Macitentan, n, (%) 15 (1.9) 8 (2.0) 7 (1.7) 3 (1.3) 4 (2.2)
Iloprost, n, (%) 6 (0.7) 4 (1.0) 2 (0.5) 1 (0.4) 1 (0.5)
Combination therapy n, (%) 240 (18.4) 74 (11.0) 57 (9.0) <0.0001 96 (28.5) 70 (23.7) 0.0003
Beraprost-Bosentan, n, (%) 79 (32.9) 13 (17.6) 66 (39.8) <0.0001 30 (31.3) 36 (51.4) 0.0035
Bosentan-Sildenafil, n, (%) 43 (17.9) 8 (10.8) 35 (21.1) 27 (28.1) 8 (11.4)
Macitentan-Sildenafil, n (%) 43 (17.9) 19 (25.7) 24 (14.5) 17 (17.7) 7 (10.0)
Beraprost-Bosentan-Sildenafil, n (%) 17 (7.1) 3 (4.1) 14 (8.4) 10 (10.4) 4 (5.7)
IPAH, idiopathic pulmonary arterial hypertension; APAH, acquired pulmonary arterial hypertension; PAH, pulmonary arterial hypertension
https://doi.org/10.1371/journal.pone.0209148.t002
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[15] In addition, several studies have described the cause of systemic hypertension in pulmo-
nary hypertension as left ventricular diastolic dysfunction and heart failure of preserved ejec-
tion fraction (HFPEF).[21–23] Compared with previous registries, the most notable difference
in the KORPAH registry and a limitation in the PAH patients of the HIRA database was the
performance rate of RHC. The rate of RHC increased yearly, reaching about 40% in the last
year, but overall among the 1307 patients, only 328 patients (25.1%) underwent RHC. RHC
was performed slightly more frequently in APAH than in IPAH patients (28.0% vs. 22.4%,
p = 0.02). PAH is diagnosed with RHC (mean pulmonary artery pressure (mPAP)�25
mmHg, pulmonary artery wedge pressure (PAWP)�15 mmHg, and pulmonary vascular
resistance (PVR)>3 Wood units). Therefore, the unknown occurrence of RHC in the patients
of this cohort and RHC performed in approximately 25% of patients may be a limitation to
PAH validation. For example, there may be doubt as to whether post-capillary PH was ade-
quately excluded, and right ventricular systolic pressure (RVSP) may have been overestimated
on echocardiography performed for RHC. In the KOPARH registry as well as in this cohort,
the underuse of RHC suggests the attitude of physicians towards the Korean PAH diagnosis.
In fact, PAH diagnoses by cardiologists, who have easy to access to RHC, were approximately
50% half[18], while the remainder were diagnosed in rheumatology or pulmonology units. In
Fig 4. Distribution and trend of prescribed pulmonary arterial hypertension-specific drugs.
https://doi.org/10.1371/journal.pone.0209148.g004
Incident pulmonary artery hypertension in Korea
PLOS ONE | https://doi.org/10.1371/journal.pone.0209148 December 19, 2018 8 / 13
Korea, the cost burden on medical expenses is relatively limited. Therefore, the proportion of
physicians or patients who is reluctant to order further testing is low. In addition, due to dis-
ease severity at the time of diagnosis (in KORPAH, NYHA Class III, IV patients accounted for
about 43%), the patient’s condition may not have been suitable for performing RHC testing
and an alternative test may have been performed. However, in order to exclude a PH of groups
2–5 including post-capillary PH, we excluded the corresponding diagnosis for each group.
Therefore, the merits of this study were that pure, incident PAH patients were identified in
nation-wide based database.
Another difference from other studies was the slightly higher proportion of IPAH (51.6%)
patients than in other registries. This was likely due to the impossibility of distinguishing the
exact diagnosis from the ICD-10 codes. As shown in S3 Table, IPAH and APAH diagnoses are
combined in code I27.0. Also, I27.2 codes contain sub-diagnostic codes for both PH and PAH.
In addition, it is believed that differential diagnostic tests (such as the pulmonary function test
[PFT], RHC, chest high resolution computed tomography [HRCT], HIV testing, or autoim-
mune testing) were infrequent in patients diagnosed with IPAH.
Estimating mortality using ICD codes for hospital mortality is likely to be underestimated.
The maximum number of prescription days available at medical institutions in Korea is 180
days. Because we determined that the number of days between hospital visits could be longer
than the number of days prescribed depending on the patient’s compliance, we defined death
as having no medical claim for over one year. Therefore, compared to the real world, the one-
year mortality rate may be relatively low and other mortality rates may be judged to be higher.
Fig 5. The trend of right catheter catheterization according to etiology in newly diagnosed patients per year. IPAH, idiopathic pulmonary arterial hypertension;
APAH, acquired pulmonary arterial hypertension.
https://doi.org/10.1371/journal.pone.0209148.g005
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Nonetheless, the survival rates at 1, 2, and 3 years were lower than those of other registries. In
this regard, more specialized medical therapies are needed to improve the survival of patients
with PAH in Korea. In addition, a follow-up study will need to investigate the outcome of pul-
monary arterial hypertension-specific therapy. Recently, Tamura et al.[24] reported on the
effectiveness and outcome of pulmonary arterial hypertension-specific therapy in Japanese
patients with pulmonary arterial hypertension. This study will be helpful for follow-up studies.
The strength of this study was that we were able to identify the medications used to treat
patients. Guidelines recommend the use of monotherapy of CCB, all licensed ERA drugs
(ambrisentan, bosentan, and macitentan), and PDE5-i drugs (sildenafil and tadalafil), iloprost,
and treprostinil as class I agents according to the World Health Organization functional class
(WHO-FC).[25] Approximately 20% of patients received non-target therapy (CCB), 18%
received PAH-specific monotherapy, and 62% received PAH-specific combination therapy.
However, the proportion of PAH-specific therapies in patients who were followed up annually
increased, and in particular, the proportion of patients given combination therapy gradually
increased. We defined PAH as ICD codes I27.0 or I27.2 and use of medication for PAH. There
may be questions about whether CCB is used in patients with hypertension (33.0% of the total
patients) or arrhythmia (6.2% of the total patients), but not for PAH. Therefore, it may be a
limitation of this study that there may have been an overestimation of patients who are pre-
scribed CCB as a hypertension treatment for PH. However, in contrast, it means that the PH is
not treated, and the inclusion of CCB drugs does not lead to overestimation, but rather it indi-
cates the realities of patient treatment for hypertension. Considering that the proportion of
patients who underwent conventional treatment in the KORPAH registry was about 27%, this
cannot be judged as overestimated. As this cohort contains data regarding all drug prescrip-
tions, further investigation in relation to the distribution of drug use, the trends of change, and
the outcome of patients is expected.
Another strength of this study is that we enrolled patients with pure incident cases without
referral bias (which reflects characteristics of patients referred to a specific hospital) and bias
according to the practice pattern (subspecialty). This study overcomes referral bias with the
use of nationwide registry covering all Korean patients. Therefore, patient characteristics
(mortality rate, etc.) and comorbidity prevalence (HTN, etc.) of this study can be more accu-
rately reflected in the real world. About 60% over of PAH patients received PAH-specific treat-
ment in the KOPARH registry, meanwhile in this study, 80% patients received PAH-specific
treatment. This difference can be explained by the practice pattern bias. In KORPAH, a large
number of patients were enrolled based on echocardiography in a specific department (rheu-
matology department), and PAH-specific treatments were often not received in the depart-
ment despite the diagnosis of PAH.
Limitations
This study has some limitations. First, it was subject to all the limitations inherent to a retro-
spective cohort analysis. Second, certain baseline parameters were not recorded. Thus, we
could not obtain information regarding clinical parameters (echocardiographic parameters,
6-minute walking distance, pulmonary vascular resistance, and WHO-FC) of patients with
PAH. Therefore, prognosis according to the functional class could not be analyzed. Third, we
validated PAH based on disease codes and medication prescribed. Prescriptions of CCB and
specific agents (ERA, PDE5-i, and PG analogues) were used to validate patient diagnosis of
PAH. However, CCB (diltiazem, amlodipine, and nifedipine) are also usually prescribed for
blood pressure control in patients with hypertension and for heart rate control in patients with
atrial fibrillation. The dosage of CCB for treating PAH is high; however, if we identified the
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prescribed dose for the patient, it was possible to accurately validate PAH cases. Because we
could not confirm the prescribed dose, it is possible that PAH incidence is overestimated.
Fourth, in case wherein the physician does not enter all the diagnoses in the database, classifi-
cation of the etiology by the ICD code alone is not accurate. Particularly ICD codes I27.0 and
I27.2 include mixed IPAH and APAH (diagnostic ICD codes I27.0 and I27.2 are described in
S3 Table). Fifth, in-hospital death was confirmed by a specific code in the medical claim, but it
was not known whether the death was related to PAH. If there was no claim for more than one
year, it was considered death even if the cause of death was not confirmed. Although there was
an advantage of being able to investigate the use of drugs in detail, the HIRA database does not
include the WHO-FC, and thus, we could not assess the appropriateness of PAH-specific drug
use according to the functional classification recommended by the guidelines. It cannot be
determined whether appropriate medication was prescribed to suitable patients.
Conclusions
We report the clinical data of 1,307 patients with PAH in Korea in this article. Compared to
other registries, including a previous Korean registry, the cohort of patients with PAH in the
HIRA database exhibited a similar distribution of age, sex, and survival rates. However, in
terms of etiology, this cohort showed higher incidences of IPAH and CTD than other regis-
tries. Additionally, as class I is recommended in the PAH guidelines, the results of medication
prescription distribution showed that most patients received monotherapy (CCB or bosentan).
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